Sign in Sign up for free

Last updated: 14 November 2023 at 9:09pm EST

Jonathan Schwartz Net Worth




The estimated Net Worth of Jonathan David Schwartz is at least $3.96 Million dollars as of 17 February 2023. Jonathan Schwartz owns over 3,557 units of Rocket Pharmaceuticals Inc stock worth over $1,799,210 and over the last 7 years he sold RCKT stock worth over $806,246. In addition, he makes $1,356,680 as Chief Medical Officer at Rocket Pharmaceuticals Inc.

Jonathan Schwartz RCKT stock SEC Form 4 insiders trading

Jonathan has made over 3 trades of the Rocket Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,557 units of RCKT stock worth $67,796 on 17 February 2023.

The largest trade he's ever made was exercising 224,529 units of Rocket Pharmaceuticals Inc stock on 1 February 2021 worth over $276,171. On average, Jonathan trades about 19,506 units every 53 days since 2018. As of 17 February 2023 he still owns at least 94,546 units of Rocket Pharmaceuticals Inc stock.

You can see the complete history of Jonathan Schwartz stock trades at the bottom of the page.





Jonathan Schwartz biography

Dr. Jonathan Schwartz M.D. serves as Chief Medical Officer of the Company. He joined us as Chief Medical Officer in January 2018 in connection with the Reverse Merger. Dr. Schwartz joined Private Rocket in January 2016 and served as Chief Medical Officer and Head of Clinical Development. Dr. Schwartz is responsible for leading our medical and program development. Dr. Schwartz has over 20 years of combined clinical practice and drug development experience. Prior to Private Rocket, Dr. Schwartz was Vice-President of Clinical Development at Stemline Therapeutics, where he oversaw development efforts for anticancer, vaccine and small-molecule platforms, a position he held since 2014. Prior to Stemline, he spent seven years at Eli Lilly and Company in several leadership positions, including Vice-President of Clinical Science, where he led development teams for numerous drug programs including ramucirumab. Previously, Dr. Schwartz was Associate Professor of Medicine at the Mount Sinai Medical Center in New York, specializing in the treatment and translational research of hepatobiliary malignancies and also served as Director for the Hematology-Oncology Fellowship training program. He has a BA in American Civilization from Brown University and an MD from Washington University (St. Louis). He completed post-graduate Internal Medicine and Hematology-Oncology training at the Mount Sinai and New York Presbyterian Hospitals.

What is the salary of Jonathan Schwartz?

As the Chief Medical Officer of Rocket Pharmaceuticals Inc, the total compensation of Jonathan Schwartz at Rocket Pharmaceuticals Inc is $1,356,680. There are 3 executives at Rocket Pharmaceuticals Inc getting paid more, with Gaurav Shah having the highest compensation of $3,883,650.



How old is Jonathan Schwartz?

Jonathan Schwartz is 56, he's been the Chief Medical Officer of Rocket Pharmaceuticals Inc since 2018. There are 4 older and 12 younger executives at Rocket Pharmaceuticals Inc. The oldest executive at Rocket Pharmaceuticals Inc is Pedro Granadillo, 73, who is the Independent Director.

What's Jonathan Schwartz's mailing address?

Jonathan's mailing address filed with the SEC is 228 STRAWBRIDGE DRIVE, SUITE 100, MOORESTOWN, NJ, 08057.

Insiders trading at Rocket Pharmaceuticals Inc

Over the last 7 years, insiders at Rocket Pharmaceuticals Inc have traded over $45,364,690 worth of Rocket Pharmaceuticals Inc stock and bought 2,407,332 units worth $48,979,646 . The most active insiders traders include Investments, Lpwong Roderic..., Mikael Dolsten, and Investments, Lpwong Roderic.... On average, Rocket Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $1,269,815. The most recent stock trade was executed by John Militello on 16 August 2024, trading 1,064 units of RCKT stock currently worth $19,684.



What does Rocket Pharmaceuticals Inc do?

rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.



What does Rocket Pharmaceuticals Inc's logo look like?

Rocket Pharmaceuticals Inc logo

Complete history of Jonathan Schwartz stock trades at Tabula Rasa HealthCare Inc and Rocket Pharmaceuticals Inc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
17 Feb 2023 RCKT Rocket Pharmaceuticals Inc Jonathan David Schwartz
See Remarks
 Sale 3,557 $19.06 $67,796
17 Feb 2023
94,546 ↗
30 Mar 2022 RCKT Rocket Pharmaceuticals Inc Jonathan David Schwartz
See Remarks
 Sale 45,000 $16.41 $738,450
30 Mar 2022
179,529 ↗
1 Feb 2021 RCKT Rocket Pharmaceuticals Inc Jonathan David Schwartz
See Remarks
 Option 224,529 $1.23 $276,171
1 Feb 2021
224,529 ↗


Rocket Pharmaceuticals Inc executives and stock owners

Rocket Pharmaceuticals Inc executives and other stock owners filed with the SEC include: